A recent study compared the safety and efficacy of multiple chemotherapy agents in treating advanced liposarcoma. READ MORE
Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.
A recent study compared the safety and efficacy of multiple chemotherapy agents in treating advanced liposarcoma.
While the overall risk of secondary cancers after Kaposi sarcoma has declined in people with HIV/AIDS, clinicians should be aware that certain cancers are becoming increasingly common in the highly active antiretroviral therapy era compared with the pre-HAART era.
Researchers compared a combination regimen with the current standard of care for first-line treatment of advanced soft-tissue sarcoma.
Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors.
Research in Review
The best potential strategy involving tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors has been identified.
Kaposi Sarcoma (KS) skin lesions are more likely to respond to local external beam radiotherapy than repeat radiotherapy.
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors, supporting efforts for further research.
Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma who are at high-risk of recurrence.